How to access Evrysdi from Egypt, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Egyptian child, adolescent, or adult diagnosed with spinal muscular atrophy (SMA) may receive a prescription for Evrysdi (risdiplam) from their treating paediatric or adult neurologist. Evrysdi is FDA-approved across SMA populations from infancy through adulthood, developed by Roche in partnership with PTC Therapeutics and the SMA Foundation. Because Evrysdi is an oral liquid taken at home rather than requiring repeat intrathecal procedures, it has meaningful practical advantages for families managing lifelong SMA care. In Egypt, Evrysdi access through public pharmacies varies, which is why your neurologist may be navigating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Evrysdi in Egypt
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Evrysdi is a small-molecule SMN2 splicing modifier that increases functional SMN protein production in patients with SMA. It is taken as an oral liquid once daily, dosed by weight and age per FDA labeling. Eligibility is based on genetic confirmation of SMA, biallelic pathogenic variants in SMN1, and ongoing management by a neurologist familiar with SMA. Your neurologist will confirm diagnosis, baseline motor function (for example using age-appropriate standardised scales), and set up periodic monitoring. Evrysdi's oral home-dosing profile makes it particularly suitable for paediatric outpatient management.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Evrysdi legally importable into Egypt?
Yes, through the Egyptian Drug Authority (EDA) named-patient / compassionate-use import framework. The EDA (which succeeded the Central Administration of Pharmaceutical Affairs as the country's primary medicines regulator) administers a named-patient mechanism that allows an Egypt-licensed physician to request import of a medicine not locally registered when: (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility, and (d) chain of custody is documented end to end.
For SMA, a rare paediatric and adult neurological disease, Egypt has growing experience with named-patient imports, often coordinated through tertiary children's hospitals in Cairo, Alexandria, and other governorate capitals.
How the pathway works, step by step
- Consultation with your treating neurologist. Genetic confirmation of SMA and a written clinical rationale documenting type, motor function status, and Evrysdi as the indicated treatment.
- Baseline assessment. Weight, age-appropriate motor-function measurement, and any swallowing or respiratory considerations are documented.
- EDA named-patient application. The physician or hospital files the application with clinical rationale, genetic report, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Evrysdi from authorised distribution.
- Cold-chain shipment. Evrysdi requires cold-chain handling prior to reconstitution; the product ships with temperature monitoring and chain-of-custody documentation.
- Arrival, reconstitution, and dispensing. The hospital pharmacy reconstitutes the oral solution per the manufacturer's instructions and dispenses with weight-based dosing instructions for the family.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming SMA diagnosis, genetic report, type classification, and Evrysdi as the indicated treatment
- Verification of their Egyptian medical licence
- A copy of the SMN1 genetic diagnostic report
- Patient identifier (national ID reference where required)
- Planned dosing schedule based on the patient's weight and age, and a plan for weight-based dose adjustments as a child grows
Reserve Meds provides a physician documentation kit that bundles the templates EDA reviewers expect to see, including the pediatric dosing and growth-adjustment plan that is specific to weight-based oral SMA therapy.
Costs and timing
The cost of Evrysdi is highly weight-dependent because dosing scales with body weight. Medicine price: quote on request. You get a written quote for your case before you commit. International cold-chain logistics, customs clearance, EDA documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling basis against your monthly schedule.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: Egyptian families managing paediatric rare disease often rely on extended-family support networks. Our coordination includes whichever family members, a parent in Cairo, a brother in the Gulf, a cousin in Europe, the primary caregiver designates.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Evrysdi specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for EDA / customs review.
- Logistics. Cold-chain, temperature-monitored shipment with customs clearance support.
- Dedicated case lead. A named point of contact for the family, coordinating long-term refills and weight-based dose adjustments as the child grows.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Egypt? Yes, when executed through the EDA named-patient / compassionate-use framework with appropriate documentation. Cross-border named-patient import for rare-disease therapies is a recognised mechanism in Egypt. See our trust and compliance page.
Is Evrysdi suitable for adults? Yes, Evrysdi's FDA label covers SMA across age ranges including adults. Your neurologist will confirm age- and type-appropriate dosing.
Will the dose need to change as the child grows? Yes. Evrysdi is weight-based; your neurologist will adjust the dose as your child grows. Our refill coordination accommodates dose changes without supply gaps.
How is it taken? Evrysdi is an oral solution taken once daily, typically after a meal for adults and older children, and per physician instructions for infants. A feeding-tube administration route is also described in the FDA label.
Will insurance cover this? Cash-pay is the default. Some Egyptian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Evrysdi coordination in Egypt, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Evrysdi in Egypt if it is not approved or available there?
Reserve Meds coordinates US-sourced Evrysdi for patients in Egypt through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Egypt and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Evrysdi in Egypt through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Evrysdi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Egypt, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Evrysdi in Egypt through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Evrysdi to a patient in Egypt?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Evrysdi to your treating physician or hospital pharmacy in Egypt, with appropriate handling for the product.
How long does it take, and what does Evrysdi in Egypt cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Evrysdi in Egypt?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.